^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GTB-5550

i
Other names: GTB-5550, B7-H3 TriKE, cam16-IL15-camB7H3, GTB5550, GTB 5550
Company:
GT Biopharma
Drug class:
NK cell stimulant, CD16 agonist, B7-H3 inhibitor, IL-15 stimulant
Related drugs:
2years
B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma (ASH 2022)
B7-H3 TriKE may be particularly useful for patients with bone lesions or as consolidative therapy. Commercial manufacturing of B7-H3 TriKE (GTB-5550) has begun, and a phase I trial is expected in late 2023.
IL6 (Interleukin 6) • CD276 (CD276 Molecule) • CD33 (CD33 Molecule) • S100A8 (S100 Calcium Binding Protein A8) • SDC1 (Syndecan 1) • CD14 (CD14 Molecule) • CSF2 (Colony stimulating factor 2) • ITGAM (Integrin, alpha M) • IL15 (Interleukin 15) • TNFRSF11A (TNF Receptor Superfamily Member 11a)
|
GTB-5550
over2years
B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells (ESMO 2022)
As proof of concept, a clinical trial of GTB-3550 (a CD33-targeted Tri-specific Killer Engager [TriKE] in AML) induced endogenous NK cell expansion and activation in refractory AML patients. Here we developed GTB-5550 (a B7H3 TriKE) as a novel dual camelid (cam) TriKE containing WT IL-15 and comprised of two cam engagers: targeting CD16 on NK cells and B7H3 on multiple solid tumors...Conclusions B7H3 TriKE delivers an NK cell specific IL-15 signal to expand NK cells and is highly specific against a broad array of cancers. Clinical manufacturing is underway with an IND planned to open clinical trials in 2023 in a number of solid tumors and multiple myeloma.
Pan tumor
|
CD276 (CD276 Molecule) • CD33 (CD33 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • IL15 (Interleukin 15)
|
GTB-5550 • GTB-3550 TRIKE
over2years
GTB-5550 (cam16-IL15-camB7H3) trispecific killer engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas (AACR 2022)
NK cell degranulation and IFN-gamma production of GTB-3550-treated samples were higher compared to that of control samples treated with B7H3 single domain or IL-15 alone. Ongoing experiments will evaluate functionality of GTB-5550 on FA patient samples as well as in spheroid assays. Taken together, this data shows that a GTB-5550 is able to drive NK cell activity against B7H3-expressing HNSCC cells, which presents potential for a B7H3-targeted TriKE to be used to be implemented clinically to treat HNSCC or FA-HNSCC patients.
IO biomarker
|
IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • FANCA (FA Complementation Group A) • CD28 (CD28 Molecule) • IL15 (Interleukin 15)
|
CD276 expression
|
GTB-5550 • GTB-3550 TRIKE